Agonistic stimulation of 4-1BB (urelumab) during the pre-REP phase tends to promote less differentiated TIL subsets but fails to preserve them during the rapid expansion protocol (REP)
Аннотация
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) is a promising immunotherapy that relies on the isolating, expansion, and reinfusion of TILs derived from resected tumors. Traditionally, TIL isolation relies on high-dose IL-2. However, recent protocols incorporate CD3 (OKT3) and 4-1BB (urelumab) agonism to mimic the three canonical T-cell activation signals [1]. While this approach has been associated with reduced culture times, enhanced CD8⁺ T-cell expansion, and a broader TCR repertoire in melanoma and lung cancer [2, 3], its precise impact on TIL phenotype remains insufficiently characterized. We evaluated TILs from eight melanoma tumors expanded with IL-2 and OKT3, with or without urelumab, during the pre-rapid expansion protocol (pre-REP) phase. Cultures were analyzed by multiparametric flow cytometry for memory, activation, and exhaustion markers, supported by automated clustering, RNA sequencing, and TCR repertoire profiling. Initial three-signal stimulation showed a tendency toward faster outgrowth (15.7 vs. 25 days) and a higher yield of successful fragments. While overall CD3⁺ cell proportions remained stable (> 90%), multiple activation signals favored CD8⁺ T-cell expansion. Phenotypically, pre-REP urelumab supplementation show a tendency to preserve less differentiated subsets expressing makers associated with tumor reactivity (PD-1+ and CD69−CD39−), alongside a trend toward greater TCR diversity and reduced clonality. Gene Set Enrichment Analysis (GSEA) further identified the enrichment of a gene signatures linked to favorable clinical response in the urelumab group. Importantly, while urelumab during pre-REP favored potentially beneficial subsets, these advantages were not sustained during the subsequent rapid expansion protocol (REP). Instead, urelumab reduced overall TIL yield, failed to preserve CD27 or CD28 expression, and promoted exhausted phenotypes and functional impairment, with only KLF2 upregulation suggesting partial induction of a CD45RA⁺CCR7⁺ subset. These findings contrast with prior studies reporting improved CD8⁺ persistence and cytotoxicity with urelumab during REP, a discrepancy likely related to the higher urelumab dose employed in our study. In conclusion, stimulation with multiple activation signals tends to promote accelerated TIL expansion and favors CD8⁺ outgrowth. While the addition of urelumab during pre-REP may enrich populations exhibiting clinically favorable biomarkers, its use during REP appears detrimental to the final cellular product. These results underscore the necessity of optimizing TIL manufacturing protocols, such as co-stimulation timing, dosing and cytokine support, to preserve clinically relevant TIL subsets for future clinical trials.